Skip to main content
Ascelia Pharma logo

Ascelia Pharma — Investor Relations & Filings

Ticker · ACE ISIN · SE0010573113 LEI · 5493002YR9VCJJPWYN08 ST Manufacturing
Open in API
Filings indexed 295 across all filing types
Latest filing 2025-09-22 Share Issue/Capital Cha…
Country SE Sweden
Listing ST ACE

About Ascelia Pharma

https://www.ascelia.com/

Ascelia Pharma is a biotechnology company focused on developing and commercializing novel drugs for orphan oncology. The company aims to address unmet medical needs for patients with rare cancer conditions. Its lead product candidate, Orviglance, is an oral manganese-based contrast agent for magnetic resonance imaging (MRI). It is designed to improve the detection and visualization of liver metastases, particularly in adult patients with severely impaired kidney function for whom existing contrast agents may be contraindicated. The company's strategy involves identifying, developing, and commercializing innovative treatments for niche cancer-related conditions.

Recent filings

Filing Released Lang Actions
Ascelia Pharma Has Completed a Directed Share Issue of Approximately SEK 30 Million
Share Issue/Capital Change Classification · 100% confidence The document is a press release announcing the completion of a directed share issue by Ascelia Pharma. It details the number of shares issued, the subscription price, the total proceeds, the rationale for the capital raise, and the impact on share capital and dilution. While it contains an attachment link, the text itself provides the full details of the transaction, making it a primary announcement of a share issue/capital change rather than just a report publication announcement. Therefore, it fits the 'Share Issue/Capital Change' category.
2025-09-22 English
Ascelia Pharma avser att genomföra en riktad nyemission av aktier om cirka 30 MSEK
Share Issue/Capital Change Classification · 100% confidence The document is a press release announcing the company's intention to conduct a directed share issue (a capital raise). It details the purpose of the capital, the bookbuilding process, and includes standard legal disclaimers regarding the offering. Since it is an announcement of a capital-raising event rather than the final report of the issuance itself, and it explicitly provides a link to the PDF of the announcement at the end, it fits the criteria for a Capital/Financing Update (CAP).
2025-09-22 Swedish
Ascelia Pharma Intends to Carry Out a Directed Share Issue of Approximately SEK 30 Million
Capital/Financing Update Classification · 100% confidence The document is a press release announcing the company's intention to conduct a 'Directed Share Issue' (a capital raise) via an accelerated bookbuilding procedure. It details the purpose of the capital, the deviation from preferential rights, and the involvement of financial advisors. While it mentions an attachment, the text itself is a formal announcement of a capital financing event, which falls under the 'Capital/Financing Update' category.
2025-09-22 English
Fenja Capital II A/S påkallar konvertering av samtliga utestående konvertibler med ett totalt nominellt belopp om 7,5 MSEK
Share Issue/Capital Change Classification · 100% confidence The document announces the conversion of convertible bonds into new shares, which directly impacts the company's capital structure and share count. This falls under the category of share issuance or capital changes. While it mentions a PDF attachment, the text itself provides the full details of the transaction, making it a primary announcement of a capital change rather than just a report publication announcement.
2025-09-02 Swedish
Fenja Capital II A/S Requests Conversion of All Outstanding Convertibles for a Total Nominal Amount of SEK 7.5 Million
Share Issue/Capital Change Classification · 100% confidence The document announces the conversion of outstanding convertible bonds into new ordinary shares, which directly impacts the company's share capital and total number of outstanding shares. This falls under the category of share issuance and capital structure changes. According to the provided definitions, 'SHA' (Share Issue/Capital Change) is the appropriate classification for announcements regarding new share issues or capital changes.
2025-09-02 English
Interim / Quarterly Report 2025
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Halvårsrapport 2025' (Half-year report 2025) and covers the period 'Januari – juni 2025'. It contains comprehensive financial data, including income statements, cash flow, and liquidity analysis, as well as detailed management commentary on business operations, clinical trial results (SPARKLE study), and future outlook. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. H1 2025
2025-08-21 Swedish

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.